Preview

Научно-практическая ревматология

Расширенный поиск

ФАКТОРЫ РИСКА РАЗВИТИЯ ГИПЕРТРОФИИ МИОКАРДА ЛЕВОГО ЖЕЛУДОЧКА У БОЛЬНЫХ ПОДАГРОЙ

https://doi.org/10.14412/1995-4484-2012-1181

Полный текст:

Аннотация

Цель — оценить влияние различных факторов на развитие гипертрофии миокарда левого желудочка (ГЛЖ) у больных подагрой. Материал и методы. В исследование включено 57 больных подагрой мужского пола. Всем больным было выполнено эхокардиографическое исследование сердца в М- и В-режимах, рассчитывался индекс массы миокарда левого желудочка (ИММЛЖ). За ГЛЖ принимали увеличение ИММЛЖ >115 г/м 2. Результаты. ГЛЖ была выявлена у 23 (40,4%) из 57 больных. Она ассоциировалась с возрастом, артериальной гипертензией, ожирением, гиперурикемией, повышением уровня С-реактивного белка.

Список литературы

1. <div><p>Lorell B.H. Transition from hypertrophy to failure. Circulation 1997; 96: 3824—7.</p><p>Molkentin J.D., Olson E.N. GATA4: a novel transcriptional regulator of cardiac hypertrophy? Circulation 1997; 96: 3833—5.</p><p>Levy D., Garrison R.J., Savage D.D. et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322(22): 1561—6.</p><p>Koren M., Richard B., Devereux M. et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345—52.</p><p>Российское медицинское общество по артериальной гипертонии. Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Системн. гипертенз. 2010; 3: 5—33.</p><p>Vakili B., Okin P., Devereux R. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334—41.</p><p>Bikkina M., Levy D., Evans J. et al. Left ventricular mass and the risk the stroke in elderly cohort: The Framingham Study. JAMA 1994; 272: 33—6.</p><p>Mensah G., Pappas T., Koren M. et al. Comparison of classification severity by blood pressure level and World Health Organization for prediction concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens 1993; 11: 1429—30.</p><p>Simone G., Mureddu G., Greco R. et al. Relation of left ventricular geometry and function to body composition in children with high causal blood pressure. Hypertension 1997; 30(P 1): 377—82.</p><p>Koren M., Ulin R., Laragh J., Devereux R. Changes in LVH predict risk in essential hypertension. Circulation 1990; 83(Suppl. III): 27—9.</p><p>Bots M.L., Nikitin Y., Salonen J.T. et al. Left ventricular hypertrophy and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Commun Health 2002; 56(Suppl. 1): 8—13.</p><p>Kuzell W.C., Schaffarzick R.W., Naugler W.E. et al. Some observations on 520 gouty patients. J Chronic Dis 1995; 2: 645—69.</p><p>Vazguez-Mellado J., Garsia C.G., Vazguez S.G. et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004; 10(3): 105—9.</p><p>Ильина А.Е., Барскова В.Г., Насонов Е.Л. Применение лозартана у больных подагрой. Кардиоваск. тер. и профилакт. 2008; 7(2): 51—3.</p><p>Weiss T.E., Segaloff A. Gouty arthritis and gout. Springfield, III: Thomas, 1959; 7.</p><p>Wyngaarden J.B., Kelley W.N. Gout and hyperuricemia. New York, 1976; 512.</p><p>The Bogalusa Heart Study: 20th Anniversary Symposium. Am J Med Sci 1995; 310(Suppl. 1): 1 — 138.</p><p>Alper A.B. Jr, Chen W., Yau L. et al. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005; 45: 34—8.</p><p>Sundström J., Sullivan L., D'Agostino R.B. et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45(1): 28—33.</p><p>Jossa F., Farinaro E., Panico S. et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994; 8: 677—81.</p><p>Taniguchi Y., Hayashi T., Tsumura K. et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 2001; 19(7): 1209—15.</p><p>Choi H.K., Atkinson K., Karlson E.W., Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005; 165(7): 742—8.</p><p>Kang D.-H., Nakagawa T., Feng L. et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-97.</p><p>Johnson R.J., Kang D.-N., Feig D. et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-90.</p><p>Johnson R.J., Rodriguez-Iturbe B., Kang D.H. et al. A unifying pathway for essential hypertension. Am J Hypertens 2005; 18: 431—40.</p><p>Nakagawa Т., Mazzali M., Kang D.-H. et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003; 23: 2-7.</p><p>Mazzali M., Hughes J., Kim Y.G. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38(5): 1101—6.</p><p>Mazzali M., Kanellis J., Han L. et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 6: 991-7.</p><p>Alderman M.N., Cohen H., Madhvan S. et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-50.</p><p>Campo C., Ruilope L.M., Segura J. et al. Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. Blood Press 2003; 12: 277-83.</p><p>Viazzi F., Parodi D., Leoncini G. et al. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005; 45: 991—6.</p><p>Iribarren C., Folsom A.R., Eckfeldt J.H. et al. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC study. Ann Epidemiol 1996; 6: 331-40.</p><p>Cuspidi C., Valerio C., Sala C. et al. Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. Am J Hypertens 2007; 20: 678—85.</p><p>Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.</p><p>Kuo C.-F., Yu K.-H., Luo S.-F. et al. Role of uric acid in the link between arterial stiffness and cardiac hypertrophy: a cross-sectional study. Rheumatology (Oxford) 2010; 49(6): 1189—96.</p><p>Tsioufis C., Stougiannos P., Kakkavas A. et al. Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension. Am J Cardiol 2005; 96(2): 252—6.</p><p>Schumacher H.R. Jr. Crystal-induced arthritis: an overview. Am J Med 1996; 100: 46-52.</p><p>Reichek N., Devereux R.B. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 1981; 63: 1391-8.</p><p>Wallace S.L., Robinson H., Masi A.T. et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthr Rheum 1977; 20: 895—900.</p><p>World Health Organization (WHO). Obesity: prevention and management of the global epidemic. Report of the WHO Consultation. World Health Organ Tech. Rep Ser 2000; 894(i—xii): 1 —253.</p><p>World Health Organization (WHO). Prevention and management of the global epidemic of obesity. Report of the WHO Consultation on Obesity. Geneva: WHO, 1997.</p><p>Seidell J. Obesity in Europe. Obes Res 1995; 3(Suppl. 2): 89s—93s.</p><p>Stern J., Hirsch J., Blair S. et al. Weighting the options: criteria for evaluating weight-management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Obes Res 1995; 3(6): 591—604.</p><p>Mancia G., de Backer G., Dominiczak A. et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESC). J Hypertens 2007; 25(6): 1105—87.</p><p>Devereux R.B., Alonso D.R., Lutas E.M. et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57(6): 450—8.</p><p>Lang R.M., Bierig M., Devereux R.B. et al.; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group... J Am Soc Echocardiogr 2005; 18(12): 1440—63.</p><p>Васюк Ю.А. Функциональная диагностика в кардиологии: клиническая интерпретация. М.: Практическая медицина, 2009; 312 с.</p><p>Schillaci G., Verdecchia P., Porcellatti C. et al. Continuous relation between left ventricular mass and cardiovascular risk is essential hypertension. Hypertension 2000; 35: 580-6.</p><p>Gottdienner J.S., Reda D.J., Materson B.J. et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol 1994; 24: 1492-8.</p><p>Poirier P., Giles T., Bray G. et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effects of weight loss. An update of the 1997 american heart association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism. Circulation 2006; 113: 898—918.</p><p>Neves M.F., Schiffrin E.L. Aldosterone: A risk factor for vascular diseases. Cur Hypertens Rep 2003; 5: 59-65.</p><p>Sato A., Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Intern Med Res 2001; 29: 13—21.</p><p>Hameedi A., Shadow H.L. The promise of selective aldosterone receptor antagonists for the treatment of Hypertension and Chronic Heart Failure. Cur Hypertens Rep 2000; 2: 378-83.</p><p>Мычка В.Б., Горностаев В.В., Шикина Н.Ю., Чазова И.Е. Артериальная гипертония и ожирение. Gons med 2001; 2(прил.): 17—22.</p><p>Braiser A.R., Resinos A., Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257—66.</p><p>Stenvinkel P. Endotelial dysfunction and inflammation — is there link? Nephrol Dial Transplant 2001; 16: 1968-71.</p><p>Krumholz H.M., Larson M., Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879—84.</p><p>Лазебник Л.Б., Комиссаренко И.А., Милюкова О.М. Систолическая артериальная гипертония у пожилых. Рус. мед. журн. 1997; 5(20): 6—9.</p><p>Devereux R.B., Roman M.J., de Simone G. et al. Relations of left ventricular mass to demographic and hemodynamic variables in american indians. Circulation 1997; 96: 1416-23.</p><p>Task Force of the European Society of Cardiology and North American Society of Pacing and Electrophysiology. Heart rate variability, standarts of measurements, physiological interpretation, and clinical use. Circulation 1996; 93: 1043-65.</p><p>Kannel W.B., Dannenberg A.L., Levy D. et al. Population implication of electrocardiographic left ventricular hypertrophy. Am J Cardiology 1987; 60: 851—931.</p><p>Sullivan J.M., Zwaag R.V., El-Zeky F. et at. Left ventricular hypertrophy: effect on survival. J Am Coll Cardiol 1993; 22(2): 508—13.</p><p>Verdecchia P., Schillaci G., Borgioni С. el al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol 1998; 31(2): 383—90.</p></div><br />


Для цитирования:


Маркелова Е.И., Барскова В.Г., Волков А.В., Korsakova Y.O., Ilyinykh E.V. ФАКТОРЫ РИСКА РАЗВИТИЯ ГИПЕРТРОФИИ МИОКАРДА ЛЕВОГО ЖЕЛУДОЧКА У БОЛЬНЫХ ПОДАГРОЙ. Научно-практическая ревматология. 2012;50(5):45-50. https://doi.org/10.14412/1995-4484-2012-1181

For citation:


Markelova E.I., Barskova V.G., Volkov A.V., Korsakova Yu.O., Ilyinykh E.V. RISK FACTORS FOR THE DEVELOPMENT OF LEFT VENTRICULAR MYOCARDIAL HYPERTROPHY IN PATIENTS WITH GOUT. Rheumatology Science and Practice. 2012;50(5):45-50. (In Russ.) https://doi.org/10.14412/1995-4484-2012-1181

Просмотров: 1178


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)